

## Tutorial on Comorbidity Indices in Medical Research

Muhammad Ajmal Dina <sup>1</sup> , Farzan Madadizadeh <sup>1\*</sup> , Anam Arshed <sup>2</sup> 

1. Center for Healthcare Data Modeling, Departments of Biostatistics and Epidemiology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2. Rahbar Medical and Dental College, Lahore Pakistan

### ARTICLE INFO

#### Review Article

**Received:** 13 Jan 2025

**Accepted:** 30 Apr 2025



#### Corresponding Author:

Farzan Madadizadeh  
madadizadehfarzan@gmail.com

### ABSTRACT

**Background:** Comorbidity indices, such as Charlson Comorbidity Index (CCI) and Elixhauser Comorbidity Measure (ECM), are essential tools for assessing the influence of comorbid health conditions on patient outcomes. This study aims to review comorbidity indices by assigning weighted scores to a spectrum of comorbidities; these instruments play a critical role in predicting mortality rates and evaluating healthcare resource utilization.

**Methods:** In this narrative review study, we reviewed all comorbidity indices and important points were mentioned.

**Results:** CCI and ECI have proven to be highly effective tools for predicting mortality and healthcare outcomes across a wide range of patient populations. This review examines four comorbidity indices: CCI, ECI, Acute Myeloid Leukemia (AML), and the Chronic Disease Index (CDI).

**Conclusion:** Among four types, CCI and ECM were the most applied, and the researcher should know different types of comorbidity indices to use in research.

**Keywords:** CCI (Comorbidity by Charlson Index); ECI (Elixhauser comorbidity index); AML (Acute myeloid leukemia); CDI (Chronic disease index); Indices; Research

#### How to cite this paper:

Ajmal Dina M, Madadizadeh F, Arshed A. Tutorial on Comorbidity Indices in Medical Research. J Community Health Research 2025; 14(1): 134-139.

## Introduction

Comorbidity is a term of Latin origins introduced by Alvan R. Feinstein (1925-2001), an American researcher and epidemiologist (1). According to him, it is a distinct additional clinical entity that exists or can be apparent during the clinical course of a disease that is under investigation (2). Condition of comorbidity has a potential impact on a patient's cause and alters the treatment plans with outcome. The condition of comorbidities coexists with the condition of disease interest (3), it leads to delayed diagnosis, and confounders in the analysis of course and clinical status raise the mortality and morbidity (4). Researchers investigate their statistical models to identify associations with comorbidities such as heart disease and diabetes. (5). It is widely used by researchers to summarize comorbidity measurement with adjusting outcomes via the use of health data (6). To the best of the authors' knowledge, there are four indices for comorbidity including Elixhauser comorbidity index (ECI), Charlson Comorbidity Index (CCI)), acute myeloid leukemia (AML) comorbidity index and chronic disease indicators (CDI). In the next session, the authors will review all of them.

### 1. Comorbidity indices

There were four type of CI such as CCI, ECI, AML, and CDI which will be introduced one by one in following sub-sections.

#### 1.1 CCI

CCI was introduced by Charlson with his fellows in 1987, they classified the comorbidity conditions that can influence a risk of mortality (7). CCI is used to determine survival rates 1 year to 10 years in patients with multiple comorbidities used in longitudinal studies (8). CCI score estimates a patient's survival of 10 years rate with multiple comorbidities (9).

According to the protocol, CCI has assigned a numerical score for single comorbidity, and the sum of the score provides a quantitative measure of the patient's overall health (10). Before checking the CCI score, first we should identify medical professionals and document the comorbidity that

the patient has (9). Chronic diseases have mostly had conditions in general, and many health issues can affect the patient's prognosis, treatment, and outcomes (11).

**Table 1.** CCI and its weight

| Condition                         | Weight |
|-----------------------------------|--------|
| Myocardial infarction             | 1      |
| Congestive heart failure          | 1      |
| Peripheral vascular disease       | 1      |
| Cerebrovascular disease           | 1      |
| Dementia                          | 1      |
| Chronic pulmonary disease         | 1      |
| Connective tissue disease         | 1      |
| Ulcer disease                     | 1      |
| Mild liver disease                | 1      |
| Diabetes without end-organ damage | 1      |
| Hemiplegia                        | 2      |
| Moderate or severe renal disease  | 2      |
| Diabetes with end-organ damage    | 2      |
| Any tumor                         | 2      |
| Leukemia                          | 2      |
| Lymphoma                          | 2      |
| Moderate or severe liver disease  | 3      |
| Metastatic solid tumor            | 6      |
| AIDS                              | 6      |

Source: "Charlson Comorbidity Index: A Critical Review of Clinimetric Properties"(9)

A specific eight number for each comorbidity is assigned and scored depending on the severity and impact on his / her mortality(6). Once scores of comorbidities are identified, they are summed to calculate the CCI score, the score ranges from 0 to 37 or more (12), depending on comorbidities on the number and severity. If CCI score is higher, it indicates a high burden of comorbidities, and a high risk of complications with mortality, or adverse outcomes (13).

#### 1.2 ECI

ECI has included 29 comorbidities (14). ECI is a widely applied tool in healthcare clinical practice and research for assessing comorbid conditions in patients (15). It was developed in 1998 by Elixhauser and aims to provide a standard and comprehensive measure of comorbidity by

identifying and quantifying various medical conditions that coexist alongside a patient's primary diagnosis (16). The Elixhauser

comorbidity index encompasses a wide range of conditions and is a valuable tool for clinicians, researchers, and policymakers (17).

**Table 2.** Table of the Elixhauser comorbidities, their descriptions, and van Walraven weights

| Comorbidity                                     | Description/Example   | Van Walraven Weight |
|---|---|---------------------|
| Congestive heart failure                        | Heart failure   | 7                   |
| Cardiac arrhythmias                             | Atrial fibrillation, ventricular tachycardia                    | 5                   |
| Valvular disease                                | Mitral valve disease, aortic stenosis                           | -1                  |
| Pulmonary circulation disorders                 | Pulmonary hypertension, pulmonary embolism                      | 4                   |
| Peripheral vascular disorders                   | Peripheral artery disease, claudication                         | 2                   |
| Hypertension (uncomplicated)                    | High blood pressure without end-organ damage                    | 0                   |
| Hypertension (complicated)                      | High blood pressure with end-organ damage (e.g., renal failure) | -1                  |
| Paralysis                                       | Paraplegia, hemiplegia, quadriplegia                            | 7                   |
| Other neurological disorders                    | Parkinson's disease, multiple sclerosis                         | 6                   |
| Chronic pulmonary disease                       | COPD, asthma, pulmonary fibrosis                                | 3                   |
| Diabetes (uncomplicated)                        | Diabetes without complications                                  | 0                   |
| Diabetes (complicated)                          | Diabetes with complications (e.g., retinopathy, neuropathy)     | -3                  |
| Hypothyroidism                                  | Underactive thyroid   | 0                   |
| Renal failure                                   | Chronic kidney disease, end-stage renal disease                 | 5                   |
| Liver disease                                   | Cirrhosis, hepatitis  | 11                  |
| Peptic ulcer disease                            | Gastric or duodenal ulcers                                      | 0                   |
| AIDS/HIV  | Acquired immunodeficiency syndrome                              | 0                   |
| Lymphoma  | Hodgkin's or non-Hodgkin's lymphoma                             | 9                   |
| Metastatic cancer                               | Cancer with metastasis  | 12                  |
| Solid tumor without metastasis                  | Localized cancer  | 4                   |
| Rheumatoid arthritis/collagen vascular diseases | Lupus, rheumatoid arthritis, scleroderma                        | 0                   |
| Coagulopathy                                    | Bleeding disorders, clotting disorders                          | 3                   |
| Obesity   | Body mass index (BMI) $\geq 30$                                 | -4                  |
| Weight loss                                     | Malnutrition, cachexia  | 9                   |
| Fluid and electrolyte disorders                 | Hyponatremia, hyperkalemia                                      | 5                   |
| Blood loss anemia                               | Anemia due to acute blood loss                                  | -2                  |
| Deficiency anemia                               | Iron deficiency anemia, vitamin B12 deficiency                  | -2                  |
| Alcohol abuse                                   | Alcohol dependence or abuse                                     | 0                   |
| Drug abuse                                      | Substance abuse   | -7                  |
| Psychoses                                       | Schizophrenia, bipolar disorder                                 | -5                  |
| Depression                                      | Major depressive disorder                                       | -3                  |

Source: "Development and validation of a structured query language implementation of the Elixhauser comorbidity index"(18).

The Elixhauser Comorbidity Index (ECI) is a method for categorizing comorbidities in patients, based on diagnosis codes from the International Classification of Diseases (ICD) (16), and it is found in administrative data, like hospital abstracts data. ECI scoring ranges from -7 to +12 (19) (20). The score of >15 is used as a cut-off value (21) and it is with a 1-year mortality of 38% (22).

### 1.3 AML

AML comorbidity index is another comorbidity index. The panel of international expert in 2010, with the recommendation of the European Leukemia Net (ELN), published advice for the diagnosis and management of AML. AML-C is the most important tool in hematology and oncology field and is designed to assess the presence of comorbidities diagnosed with acute myeloid leukemia (AML) patients (23). AML's relative

survival rate in 5 years is 29.8% (24), but it depends on age, health condition, and genetically specific mutations present in the leukemia cells. In general, a 5-year relative survival rate for AML is 29.8% (25), the viewpoint for an individual will depend on age, health condition, the particular hereditary changes displayed within the leukemia cells with other variables (26).

2.4 CDI

CDI is a critical metric used in epidemiology and public health research for assessing the prevalence and impact of chronic diseases in specific populations (27). This index has a role in understanding the burden of chronic diseases on healthcare systems individually. The CDI provides

a comprehensive picture of the occurrence of chronic diseases like hypertension, diabetes, heart, cancer, stroke, and arthritis in a given population over an extended period (28).

In the research, various factors were calculated by researchers in the CDI, such as cases, disease duration, and overall population size (29). The aim was to make a standardized measure used to compare the prevalence of chronic diseases in different regions, timeframes, and demographics. CDI is a valuable tool for policymakers and healthcare professionals (30). It helps them to identify a high-burden area of chronic diseases, allocate resources effectively, and help target interventions to mitigate the impact of these conditions.

Table 3. The advantages and disadvantages of different comorbidity indices

| Comorbidity indices | Advantages   | Disadvantages   |
|---------------------|--|---|
| CCI                 | Simple and widely validated for mortality prediction.<br>Easy to apply in clinical and research settings.<br>Focuses on a concise set of comorbidities.                        | Limited to 17 conditions, potentially overlooking other significant comorbidities.<br>Less comprehensive than newer indices.<br>Does not include mental health conditions |
| ECI                 | Includes 30 comorbidities, offering a broader scope.<br>Superior in predicting in-hospital mortality.<br>Can be weighted (e.g., van Walraven score) for enhanced precision.    | More complex to implement due to the larger number of conditions<br>Requires detailed administrative data<br>May overcomplicate risk assessment in some settings          |
| AML                 | Specific to hematologic malignancies, providing tailored risk assessment<br>Useful for stratifying patients in oncology settings<br>Incorporates genetic and molecular factors | Limited to AML patients, not generalizable to other conditions.<br>Requires specialized knowledge and data.<br>Less applicable for non-cancer populations.                |
| CDI                 | Focuses on chronic diseases, relevant for long-term health management<br>Useful for population health studies<br>Can be adapted to specific chronic conditions                 | Less standardized compared to CCI or ECI<br>May lack specificity for acute outcomes like mortality<br>Limited validation in diverse clinical settings                     |

Conclusion

ECI and CCI are among the most widely used assessment tools globally. Among these, the ECI demonstrates superior accuracy in predicting in-hospital mortality. When a weighted scoring system is applied to evaluate patient outcomes, ECI score proves to be particularly precise. Its comprehensive inclusion of comorbidities

enhances its predictive capability, making it a valuable tool for assessing healthcare outcomes and resource allocation.

Acknowledgments

We acknowledge all my teachers who made this study possible.

Conflicts of interest

All authors have declared no conflicts of interest.

### Ethical considerations

Not applicable.

### Code of ethics

Not applicable.

### Funding

No external funding was received for this study.

### Authors' contributions

M. A. D. drafted the manuscript; A. A, M. T. S, and F. M, all helped with data analysis and critical appraisal of the manuscript. All co-authors read and approved the final draft of the manuscript.

### Open access policy

JCHR does not charge readers and their institutions for access to its papers. Full text download of all new and archived papers is free of charge.

## References

1. Trüeb RM, Trüeb RM. Patient expectation management. The Difficult Hair Loss Patient: Guide to Successful Management of Alopecia and Related Conditions. 2015: 31-48.
2. Svicher A. PAINMIG: Cohort Study for the Evaluation of Mental Pain in Migraine Patients; 2020.
3. Zulman DM, Asch SM, Martins SB, et al. Quality of care for patients with multiple chronic conditions: the role of comorbidity interrelatedness. *Journal of general internal medicine*. 2014; 29: 529-37.
4. Nanayakkara N, Curtis AJ, Heritier S, et al. Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. *Diabetologia*. 2021; 64: 275-87.
5. Ssentongo P, Ssentongo AE, Heilbrunn ES, et al. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. *PloS one*. 2020; 15(8): e0238215.
6. Austin SR, Wong Y-N, Uzzo RG, et al. Why summary comorbidity measures such as the Charlson comorbidity index and Elixhauser score work. *Medical care*. 2015; 53(9): e65-e72.
7. Sinvani L, Kuriakose R, Tariq S, et al. Using Charlson comorbidity index to predict short-term clinical outcomes in hospitalized older adults. *The Journal for Healthcare Quality (JHQ)*. 2019; 41(3): 146-53.
8. Drosowsky A, Gough K. The Charlson Comorbidity Index: problems with use in epidemiological research. *Journal of clinical epidemiology*. 2022; 148: 174-7.
9. Charlson ME, Carrozzino D, Guidi J, et al. Charlson comorbidity index: a critical review of clinimetric properties. *Psychotherapy and psychosomatics*. 2022; 91(1): 8-35.
10. Asai N, Ohashi W, Sakanashi D, et al. Combination of Sequential Organ Failure Assessment (SOFA) score and Charlson Comorbidity Index (CCI) could predict the severity and prognosis of candidemia more accurately than the Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) score. *BMC infectious diseases*. 2021; 21: 1-11.
11. Grady PA, Gough LL. Self-management: a comprehensive approach to management of chronic conditions. *American journal of public health*. 2014; 104(8): e25-e31.
12. Fernando DT, Berecki-Gisolf J, Newstead S, et al. Effect of comorbidity on injury outcomes: a review of existing indices. *Annals of epidemiology*. 2019; 36: 5-14.
13. Zhang X-M, Wu X-J, Cao J, et al. Effect of the age-adjusted Charlson comorbidity index on all-cause mortality and readmission in older surgical patients: a national multicenter, prospective cohort study. *Frontiers in Medicine*. 2022; 9: 896451.
14. Whitney DG, Kamdar NS. Development of a new comorbidity index for adults with cerebral palsy and comparative assessment with common comorbidity indices. *Developmental Medicine & Child Neurology*. 2021; 63(3): 313-9.
15. Kirby JJ, Shaikh S, Bryant DP, et al. A simplified comorbidity evaluation predicting clinical outcomes among patients with coronavirus disease 2019. *Journal of Clinical Medicine Research*. 2021; 13(4): 237.
16. Oterino-Moreira I, Lorenzo-Martínez S, López-Delgado Á, et al. Comparison of three comorbidity measures for predicting in-hospital death through a clinical administrative nacional database. *International journal of environmental research and public health*. 2022; 19(18): 11262.

17. Cai M, Liu E, Zhang R, et al. Comparing the performance of Charlson and Elixhauser comorbidity indices to predict in-hospital mortality among a Chinese population. *Clinical Epidemiology*. 2020; 307-16.
18. Epstein RH, Dexter F. Development and validation of a structured query language implementation of the Elixhauser comorbidity index. *Journal of the American Medical Informatics Association*. 2017; 24(4): 845-50.
19. Soroa G, Gorostiaga A, Aritzeta A, et al. A shortened Spanish version of the Emotional Creativity Inventory (the ECI-S). *Creativity Research Journal*. 2015; 27(2): 232-9.
20. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. *American journal of epidemiology*. 2001; 154(9): 854-64.
21. Pot GK, Richards M, Prynne CJ, et al. Development of the Eating Choices Index (ECI): a four-item index to measure healthiness of diet. *Public health nutrition*. 2014; 17(12): 2660-6.
22. Huang Y-J, Chen J-S, Luo S-F, et al. Comparison of indexes to measure comorbidity burden and predict all-cause mortality in rheumatoid arthritis. *Journal of Clinical Medicine*. 2021; 10(22): 5460.
23. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood, The Journal of the American Society of Hematology*. 2010; 115(3): 453-74.
24. Roman E, Smith A, Appleton S, et al. Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004–15. *Cancer epidemiology*. 2016; 42: 186-98.
25. Delie A. Impact of new treatment guidelines pertaining to the indication for allogeneic stem cell transplantation in acute myeloid leukemia at the: Ghent University; 2018.
26. Porter CC, Druley TE, Erez A, et al. Recommendations for surveillance for children with leukemia-predisposing conditions. *Clinical Cancer Research*. 2017; 23(11): e14-e22.
27. Airlangga G. Comparative Analysis of Machine Learning Models for Chronic Disease Indicator Classification Using US Chronic Disease Indicators Dataset. *MALCOM: Indonesian Journal of Machine Learning and Computer Science*. 2024; 4(3): 1034-42.
28. Betancourt M, Roberts K, Bennett T-L, et al. Monitoring chronic diseases in Canada: the chronic disease indicator framework. *Chronic Diseases & Injuries in Canada*. 2014; 34.
29. Kuntz JL, Chrischilles EA, Pendergast JF, et al. Incidence of and risk factors for community-associated *Clostridium difficile* infection: a nested case-control study. *BMC infectious diseases*. 2011; 11: 1-7.
30. Scott RD, Slayton RB, Lessa FC, et al. Assessing the social cost and benefits of a national requirement establishing antibiotic stewardship programs to prevent *Clostridioides difficile* infection in US hospitals. *Antimicrobial Resistance & Infection Control*. 2019; 8: 1-17.